Activity of amoxicillin-clavulanate against penicillin-resistant Streptococcus pneumoniae in an experimental respiratory infection model in rats.
High doses of amoxicillin, equivalent to those produced by 500- and 750-mg oral doses in humans (area under the plasma concentration-time curve), were effective against a penicillin-resistant strain of Streptococcus pneumoniae in an experimental respiratory tract infection in immunocompromised rats; this superior activity confirms the results of previous studies. An unexpected enhancement of amoxicillin's antibacterial activity in vivo against penicillin-resistant and -susceptible S. pneumoniae strains was observed when subtherapeutic doses of amoxicillin were coadministered with the beta-lactamase inhibitor potassium clavulanate. The reason for this enhancement was unclear since these organisms do not produce beta-lactamase. The differential binding of clavulanic acid and amoxicillin to penicillin-binding proteins may have contributed to the observed effects.
Smith
G M
GM
Wells Medical, Surrey, United Kingdom.
Slocombe
B
B
Abbott
K H
KH
Mizen
L W
LW
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use*; D000818:Animals; D019540:Area Under Curve; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology; D008297:Male; D010403:Penicillin Resistance; D011008:Pneumococcal Infections / Q000175:diagnosis* / Q000382:microbiology*; D051381:Rats; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D019980:Amoxicillin-Potassium Clavulanate Combination